Tyrosine kinase inhibitorFDA-approvedSecond-line
Tagrisso
Generic name: osimertinib
How it works
Blocks the activity of a protein called EGFR, which is involved in the growth and spread of cancer cells.
Cancer types
Lung Cancer— EGFR-mutated
Efficacy
Studies show that patients with EGFR-mutated lung cancer treated with Tagrisso have a median progression-free survival of approximately 10.1 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Osimertinib and Tegavivint for Advanced Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Osimertinib with or without chemotherapy in lung cancer | Lung Cancer | phase-3 | Median progression-free survival was significantly longer with osimertinib plus chemotherapy than with osimertinib monotherapy (34.0 vs 15.6 months; difference, 18.4 months [95% CI, 9.9-22.3]) | Source → |
| Testing Osimertinib with or without Surgery for Certain Lung Cancer Patients | Lung Cancer | phase-3 | — | Source → |
| Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Evaluating Savolitinib and Osimertinib Combination for Non-Small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing Osimertinib and Carotuximab in Advanced Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| New Study Compares Effectiveness of Two Lung Cancer Treatments | Lung Cancer | observational | Aumolertinib demonstrated a superior median progression-free survival of 34.4 months compared to osimertinib's 26.9 months. | Source → |
| Assessing Osimertinib in Stage III Unresectable Non-small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Osimertinib Shows Unexpected Effect on HER2-Positive Breast Cancer | Breast Cancer | observational | — | Source → |
| Osimertinib Study for EGFR Mutation in Non-Small Cell Lung Cancer | Lung Cancer | preclinical | — | Source → |
| Combining Osimertinib and Gefitinib in Lung Cancer Patients with EGFR Mutation | Lung Cancer | phase-2 | The confirmed objective response rate was 26% (80% confidence interval: 16-39). | Source → |
| Combining pelcitoclax and osimertinib for lung cancer treatment | Lung Cancer | phase-1 | The objective response rate was 10.7% in patients previously progressed after third-generation TKI treatment+chemotherapy. | Source → |
| Combining SKB264 and Osimertinib for Lung Cancer Treatment | Lung Cancer | phase-3 | — | Source → |
| USP20 Protein Linked to Osimertinib Resistance in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Researchers Identify New Resistance Mechanism in Lung Cancer Treatment | Lung Cancer | lab-study | — | Source → |
| Alternate-day Osimertinib Dosing May Help Manage Side Effects | Lung Cancer | observational | — | Source → |
| Personalized Cancer Treatment for Rare Lung Cancer Mutations | Lung Cancer | lab-study | Treatment resulted in rapid clinical improvement and a radiologically confirmed partial remission followed by durable disease control for 18 months. | Source → |
| Osimertinib's Heart Risks Linked to Epigenetic Changes | Lung Cancer | animal-study | — | Source → |
| Osimertinib Linked to Changes in Skin Lipids | Lung Cancer | lab-study | — | Source → |
| EGFR TKI Selection in Non-Small Cell Lung Cancer Patients | Lung Cancer | observational | The median progression-free survival was 14.1 months, and the median overall survival was 24.9 months. | Source → |
| Cost of Osimertinib for Lung Cancer Treatment Raises Questions | Lung Cancer | review | First-line osimertinib improved outcomes but at ICERs of $151,922-$231,123/QALY (US) and €128,343-€273,895/QALY (Europe). | Source → |
| Understanding Resistance to Osimertinib in Lung Cancer | Lung Cancer | review | — | Source → |
| New Approaches to Treating Lung Cancer with EGFR Mutations | Lung Cancer | review | — | Source → |
| Study of Tepotinib and Osimertinib in Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Osimertinib-resistant lung cancer cells show vulnerabilities that can be targeted | Lung Cancer | lab-study | — | Source → |
| Rare EGFR Mutation Found in Lung Cancer Patient | Lung Cancer | observational | — | Source → |
| Comparing Two Treatments for Advanced Lung Cancer | Lung Cancer | phase-3 | The median overall survival was 40.5 months in the afatinib group and 37.0 months in the osimertinib group. | Source → |
| Researchers Identify New Mechanism of Resistance to Osimertinib in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Osimertinib after Chemotherapy and Radiation for Lung Cancer: Safety Findings | Lung Cancer | phase-3 | — | Source → |
| Evaluating Osimertinib in Advanced Lung Cancer Treatment | Lung Cancer | phase-2 | — | Source → |
| Afatinib May Help Overcome Resistance to Osimertinib in Lung Cancer | Lung Cancer | animal-study | Egfr V804F knock-in cells demonstrated a 5.7-10.5-fold increase in in vitro IC (mean, 8.2-fold) to osimertinib. | Source → |
| Long-term Osimertinib Therapy May Preserve Ovarian Reserve | Lung Cancer | observational | — | Source → |
| Comparing Cancer Treatments for Rare Lung Cancer Mutations | Lung Cancer | observational | Afatinib was associated with higher response rates and more frequent adverse events requiring dose reduction. | Source → |
| Combination Therapy Shows Promise in Advanced Lung Cancer | Lung Cancer | observational | — | Source → |
| Cancer Drugs Cross Placenta in Lab Study | Lung Cancer | lab-study | — | Source → |
| Researchers Find New Way to Overcome Osimertinib Resistance in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Osimertinib May Help Patients with Lung Cancer and Brain Metastases | Lung Cancer | observational | Median first-line treatment duration was significantly longer with osimertinib than with gefitinib (12.6 6.4 months; P<0.001). | Source → |
| Combining Osimertinib with STING Agonist Boosts Cancer Treatment | Lung Cancer | animal-study | — | Source → |
| Osimertinib Efficacy and Safety in Chinese Lung Cancer Patients | Lung Cancer | observational | The median overall survival was 41.0 months, and 43.1 months in patients eligible for the FLAURA trial. | Source → |
| Researchers Identify New Mechanism Behind Osimertinib Resistance in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Combining Osimertinib and Repotrectinib in Lung Cancer Treatment | Lung Cancer | phase-1 | The overall response rate was 22.2% (95% CI: 8.6-42.3), with six patients achieving confirmed PR lasting 6.9 months (95% CI: 2.7-13.1). | Source → |
| USP48 plays a key role in lung cancer resistance to a common treatment | Lung Cancer | lab-study | Genetic or pharmacological disruption of the USP48 axis achieved robust antitumor efficacy with survival benefits in orthotopic and patient-derived xenograft models. | Source → |
| Researchers Find New Way to Rechallenge Cancer Drug After Severe Reaction | Lung Cancer | observational | — | Source → |
| Testing Treatments for EGFR-Mutated Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Combination Therapy for Advanced Lung Cancer: A Clinical Trial | Lung Cancer | phase-3 | — | Source → |
| Combination Therapy for Advanced Lung Cancer After Osimertinib Failure | Lung Cancer | phase-3 | — | Source → |
| Osimertinib Efficacy Similar in Black Patients with Lung Cancer | Lung Cancer | observational | The median progression-free survival was 16.7 months in the Black patient group and 15 months in the non-Black patient group. | Source → |
| Combining two treatments may improve lung cancer outcomes | Lung Cancer | lab-study | — | Source → |
| Osimertinib Effectiveness in Lung Cancer Linked to Genetic Mutation Levels | Lung Cancer | review | — | Source → |
| Osimertinib Linked to Rare but Fatal Lung Inflammation in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Combination Therapy Trial for Advanced Lung Cancer Patients | Lung Cancer | phase-2 | — | Source → |
| Testing Combination Therapy for Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Evaluating Osimertinib for Lung Cancer with EGFR Mutation | Lung Cancer | phase-2 | — | Source → |
| Rare Lung Cancer Mutation Responds to Targeted Treatment | Lung Cancer | observational | — | Source → |
| Testing Durvalumab and Radiation Therapy in Early Stage Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Osimertinib Study for Early Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Advanced Lung Cancer Trial Investigates Tagrisso Treatment | Lung Cancer | preclinical | — | Source → |
| Rare Lung Cancer Transformation Found After Osimertinib Treatment | Lung Cancer | observational | — | Source → |
| Osimertinib Resistance in Lung Cancer Linked to Altered Lipid Metabolism | Lung Cancer | lab-study | — | Source → |
| Study of BL-B01D1 and Osimertinib for Lung Cancer Treatment | Lung Cancer | phase-3 | — | Source → |
| Osimertinib Linked to Cardiovascular Risks in Lung Cancer Patients | Lung Cancer | meta-analysis | — | Source → |
| Muscle Loss in Lung Cancer Patients on Osimertinib Treatment | Lung Cancer | observational | SMI loss was an independent predictor of shorter OS (median OS 25.5 vs. 29.8 months, aHR: 2.04 [95% CI, 1.02-4.09]; P = 0.045) | Source → |
| Osimertinib Maintains Quality of Life in Lung Cancer Patients | Lung Cancer | phase-3 | — | Source → |
| Testing Ivonescimab with Other Treatments for Non-Small Cell Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Osimertinib Resistance in Lung Cancer Linked to Metabolic Regulation | Lung Cancer | lab-study | — | Source → |
| Osimertinib, Surgery, and Radiation Therapy in Treating Non-small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing a New Combination Therapy for Advanced Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Osimertinib and Bevacizumab for EGFR Positive Non-Small Cell Lung Cancer with Brain Metastases | Lung Cancer | phase-2 | — | Source → |
| Afatinib May Help Some Lung Cancer Patients After Osimertinib | Lung Cancer | observational | — | Source → |
| Osimertinib Efficacy in Lung Cancer Patients with EGFR Mutations | Lung Cancer | observational | The overall survival was significantly longer in the postoperative group than in the Stage IV group (median: 39.2 months and 28.5 months, respectively). | Source → |
| Evaluating Osimertinib with Chemotherapy for Non-small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Comparing Cancer Treatment Models for Lung Cancer Patients | Lung Cancer | phase-3 | — | Source → |
| Durvalumab and Chemotherapy Tested in Lung Cancer Patients | Lung Cancer | phase-2 | Confirmed ORR was 16% (80% confidence interval: 7-30); response was maintained for more than 6 months in the four patients with confirmed response. | Source → |
| Sequential Afatinib and Osimertinib Therapy Shows Promise in Lung Cancer | Lung Cancer | observational | Sequential afatinib-osimertinib therapy achieved a median OS of 55 months compared to 32.3 months with alternative strategies. | Source → |
| Improving Osimertinib Resistance in Lung Cancer Cells | Lung Cancer | lab-study | — | Source → |
| TROP2 Expression May Predict Outcomes for Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Combining Osimertinib and Brain Radiation for Advanced Lung Cancer | Lung Cancer | preclinical | — | Source → |
| Combining two cancer drugs may improve lung cancer treatment | Lung Cancer | phase-3 | The combination nearly doubled progression-free survival (PFS) compared with chemotherapy (9.8 vs. 5.4 months; hazard ratio 0.34) | Source → |
| Combining Osimertinib with AKR1C3 Inhibitor May Help Overcome Lung Cancer Resistance | Lung Cancer | lab-study | — | Source → |
| Osimertinib with or without Chemotherapy in Lung Cancer Patients | Lung Cancer | phase-3 | Combining osimertinib with chemotherapy improved progression-free survival versus osimertinib alone (HR, 0.62; P < 0.001). | Source → |
| Osimertinib Linked to Increased Heart Risks | Lung Cancer | meta-analysis | — | Source → |
| Osimertinib Resistance in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Understanding Resistance to Osimertinib in Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Cancer Cells May Use Special Structures to Resist Treatment | Lung Cancer | lab-study | — | Source → |
| Cost-effectiveness of Osimertinib for Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Osimertinib May Cause Heart Problems in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Rare Lung Cancer Mutation Responds to Afatinib and Osimertinib | Lung Cancer | observational | — | Source → |
| Fatal Lung Disease Linked to Osimertinib in Lung Cancer Patient | Lung Cancer | observational | — | Source → |
| Researchers Explore Ways to Overcome Resistance to Osimertinib in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Daily Osimertinib Dose Escalation Helps Control Brain Cancer | Lung Cancer | observational | — | Source → |
| Osimertinib Resistance in Lung Cancer: A New Signaling Pathway Identified | Lung Cancer | lab-study | — | Source → |
| Osimertinib Linked to Cardiac Problems in Lung Cancer Patients | Lung Cancer | animal-study | — | Source → |
| Cost Comparison of Lung Cancer Treatments with EGFR Mutations | Lung Cancer | phase-3 | — | Source → |
| New Study Examines Combination Treatment for Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Comparing Treatments for Lung Cancer | Lung Cancer | phase-3 | Osi+CT and Ami+Laz showed no statistical difference in terms of PFS (HR 0.79, 95% CI 0.61-1.04), with PFS-RMST estimates at 30 months numerically longer with Osi+CT (22.53 vs 20.59 months). | Source → |
| Switching to Almonertinib May Help Some Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Double-dose furmonertinib shows promise for lung cancer patients resistant to osimertinib | Lung Cancer | observational | The disease control rate was 71.1% in patients taking double-dose furmonertinib, compared to 41.7% in the control group. | Source → |
| EGFR Variant Allele Frequency and Osimertinib Treatment in Lung Cancer | Lung Cancer | observational | Patients with VAF ≥30% exhibited improved outcomes compared to those with VAF <30%, with mean OS of 31.4 months versus 19.7 months (p = 0.022), and mean PFS of 25.0 months versus 18.2 months (p = 0.234). | Source → |
| Osimertinib May Help Some Lung Cancer Patients with Specific Mutation | Lung Cancer | observational | The patient achieved a progression-free survival of 10 months. | Source → |
| New Lung Cancer Mutation Emerges After Treatment | Lung Cancer | observational | The dominant target thoracic lesion decreased by 17.9% after treatment with gefitinib and trametinib. | Source → |
| Osimertinib Response Linked to Gene Mutation Frequency | Lung Cancer | observational | Patients with a variant allele frequency (VAF) ≥30% showed a mean overall survival of 31.4 months and a mean progression-free survival of 25.0 months. | Source → |
| Researchers Explore New Way to Overcome Lung Cancer Resistance to Osimertinib | Lung Cancer | lab-study | — | Source → |
| Combining Osimertinib with Astragaloside IV May Help Treat Lung Cancer | Lung Cancer | lab-study | LPs-OSI/AS reduced tumor volume by approximately 70% compared to OSI monotherapy. | Source → |
| Researchers Explore Osimertinib's Effect on HER2-positive Breast Cancer | Lung Cancer | observational | — | Source → |
| Osimertinib and Chemotherapy Combination Shows Promise in Lung Cancer | Lung Cancer | phase-3 | The experimental group demonstrated longer median progression-free survival (15.7 vs 10.6 months) and overall survival (24.6 vs 17.5 months) compared to the control group. | Source → |
| Osimertinib Effective for Lung Cancer Patients with EGFR Mutation | Lung Cancer | meta-analysis | Osimertinib demonstrated significantly superior objective response rate (ORR) compared to control treatments (relative risk [RR] = 1.59, 95% confidence interval [CI] = 1.16 to 2.17, p < .001), exceeding the minimal clinically important difference threshold. | Source → |
| Rare Lung Cancer Mutation Responds to Osimertinib Treatment | Lung Cancer | observational | The patient achieved a complete response to osimertinib treatment. | Source → |
| Genetic Changes in Lung Cancer Patients Predict Treatment Outcomes | Lung Cancer | observational | Patients with mutations in exon 5 had a hazard ratio of 7.67 for reduced treatment period and 9.29 for overall survival compared to wild-type patients. | Source → |
| New Study Examines Osimertinib Effectiveness in Lung Cancer Patients | Lung Cancer | phase-2 | The objective response rate was 61.8%, and grade 3 or higher adverse events occurred in 22.1% of the patients. | Source → |
| Eugenol May Help Overcome Lung Cancer Resistance to Osimertinib | Lung Cancer | lab-study | — | Source → |
| PD-L1 Expression May Affect Osimertinib Outcomes in Lung Cancer | Lung Cancer | meta-analysis | Higher PD-L1 expression (≥50%) was associated with a 3.03-fold increased risk of progression or death. | Source → |
| Researchers Find New Way to Overcome Osimertinib Resistance in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Osimertinib Monotherapy for Advanced Lung Cancer with Atypical EGFR Mutations | Lung Cancer | observational | Median progression-free survival was 8.8 months, and median overall survival was 28.5 months overall, 42.5 months in patients with compound EGFR mutations, and 20.0 months in those with atypical mutations alone. | Source → |
| Gene Amplification Linked to Osimertinib Efficacy in Lung Cancer | Lung Cancer | observational | Overall survival was significantly shorter for actinin-4 immunohistochemistry-positive patients than for actinin-4 immunohistochemistry-negative patients (hazard ratio, 2.76; 95% confidence interval, 1.02-7.45). | Source → |
| Understanding Drug-Tolerant Cancer Cells in Lung Cancer | Lung Cancer | lab-study | Notably, this strategy showed superior efficacy compared with osimertinib combinations with chemotherapy or AXL inhibitor in both settings. | Source → |
| PD-L1's Role in Lung Cancer Resistance to Osimertinib | Lung Cancer | lab-study | — | Source → |
| New Cancer Compound Shows Promise in Lung Cancer Research | Lung Cancer | lab-study | Compound 14l achieved the lowest IC₅₀ values and strong EGFR kinase inhibition (IC₅₀ = 50.58 ± 3.87 nM). | Source → |
| New Compound May Help Overcome Lung Cancer Resistance to Osimertinib | Lung Cancer | lab-study | — | Source → |
| Understanding Resistance to Osimertinib in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Osimertinib Effective in Advanced Lung Cancer Patients | Lung Cancer | observational | The median progression-free survival was 15.8 months, and the median overall survival was 29.3 months. | Source → |
| Osimertinib as First-Line Treatment for Lung Cancer | Lung Cancer | observational | The median first-line progression-free survival was 19.0 months in the osimertinib group. | Source → |
| PET Scans May Help Predict Lung Cancer Treatment Outcomes | Lung Cancer | observational | — | Source → |
| T cell immunity may slow down lung cancer resistance to treatment | Lung Cancer | observational | Patients with higher CXCR3CCR4CCR6CD4 T cell levels exhibited significantly enhanced PFS (p = 0.002) and OS (p = 0.0006). | Source → |
| New Study Compares Cancer Treatments for Lung Cancer Patients | Lung Cancer | meta-analysis | Osimertinib resulted in significantly longer overall survival compared to erlotinib-based regimens (HR for OS vs. erlotinib: 1.59, 95% CI 1.09-2.31). | Source → |
| Radiation Therapy Extends Time on Osimertinib for Some Lung Cancer Patients | Lung Cancer | observational | After XRT, time on osimertinib was extended for a median of 9.7 months, with a median progression-free survival (PFS) and overall survival of 6.9 and 24.4 months, respectively. | Source → |
| Osimertinib Effective in Treating Lung Cancer with Brain Metastases | Lung Cancer | observational | The CNS-ORR was 91.9% and the CNS-DCR was 100%. | Source → |
| Understanding Resistance to Lung Cancer Drugs | Lung Cancer | lab-study | — | Source → |
| Rare Side Effect of Osimertinib in Lung Cancer Treatment | Lung Cancer | observational | — | Source → |
| New Approach to Treating Lung Cancer Resistant to Osimertinib | Lung Cancer | lab-study | — | Source → |
| MDM2 protein linked to resistance to cancer treatment Osimertinib | Lung Cancer | lab-study | — | Source → |
| Comparing Treatments for Lung Cancer with EGFR Mutations | Lung Cancer | phase-3 | The median progression-free survival (PFS) did not differ significantly between 2 G EGFR-TKIs and osimertinib (del 19: 17.6 months; L858R: 20.0 months vs. 28.3 months, p = 0.081). | Source → |
| Osimertinib Helps Patient with Lung Cancer | Lung Cancer | observational | — | Source → |
| New Study Examines Treatment Options for Lung Cancer Patients | Lung Cancer | observational | The objective response rate was much higher in the immunotherapy + chemotherapy group compared with chemotherapy or osimertinib + bevacizumab group (55.56% vs. 14.81% vs. 0%). | Source → |
| Researchers Explore New Treatment for Lung Cancer Resistance | Lung Cancer | lab-study | — | Source → |
| Researchers Identify Resistance Mutations in Lung Cancer Treatment | Lung Cancer | lab-study | — | Source → |
| Osimertinib Efficacy and Safety in Advanced Lung Cancer Patients | Lung Cancer | observational | The median progression-free survival was 20.0 months and the median overall survival was 41.0 months. | Source → |
| Ganoderma Protein May Help Fight Lung Cancer Cells Resistant to Osimertinib | Lung Cancer | lab-study | — | Source → |
| New Combination Therapy Shows Promise for Lung Cancer Treatment | Lung Cancer | lab-study | — | Source → |
| Osimertinib Shows Promise in Treating Rare Lung Cancer Mutations | Lung Cancer | phase-2 | — | Source → |
| Osimertinib as Neoadjuvant Therapy for Lung Cancer | Lung Cancer | phase-2 | The major pathological response rate was 14.8% (95% CI, 4.2 to 33.7). | Source → |
| Targeted therapy shrinks lung lesions and improves bone metastases in lung cancer patient | Lung Cancer | observational | — | Source → |
| Cancer Cells Adapt to Treatment with EGFR Inhibitors | Lung Cancer | lab-study | Combining osimertinib with elesclomol significantly increases the efficacy of osimertinib, with no additional toxicity. | Source → |
| Rare Lung Cancer Mutation Responds to Osimertinib | Lung Cancer | observational | — | Source → |
| Predicting Osimertinib Effectiveness in Brain Cancer | Lung Cancer | lab-study | The radiomic model showed an area under the receiver operating characteristic curve (AUC) of 0.786 for the validation cohort. | Source → |
| Osimertinib Effective in Rare Lung Cancer Cases | Lung Cancer | phase-2 | The overall response rate was 55.0%. | Source → |
| Reduced Dosing of Osimertinib May Be a Treatment Option for Lung Cancer | Lung Cancer | observational | The objective response rate was 31.8%, and the disease control rate was 72.7%. | Source → |
| Osimertinib treatment leads to complete cancer removal in some patients | Lung Cancer | observational | — | Source → |
| CAGE protein linked to lung cancer resistance to treatment | Lung Cancer | lab-study | — | Source → |
| Understanding Resistance to Osimertinib in Lung Cancer | Lung Cancer | review | — | Source → |
| Rare Lung Cancer Case with Uncommon EGFR Mutations | Lung Cancer | observational | A reduction in the right lobe tumor and brain lesions was achieved. | Source → |
| Limited Effectiveness of Certain Cancer Drugs after Osimertinib Resistance | Lung Cancer | observational | The objective response rate was 6.9% and the disease control rate was 58.6%. | Source → |
| Osimertinib Efficacy Affected by VEGF Family Members in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Risk of Pneumonitis in Lung Cancer Patients Receiving Radiotherapy and Osimertinib | Lung Cancer | observational | — | Source → |
| New Insights into Treating a Specific Type of Lung Cancer | Lung Cancer | lab-study | Osimertinib has also been associated with cardiomyopathy (∼1.4%-2.4%) and prolongation of the QT interval (2.7%). | Source → |
| Targeted Therapy Helps Woman with Advanced Lung Cancer | Lung Cancer | observational | — | Source → |
| Rare Lung Cancer Patient Responds to Osimertinib Monotherapy | Lung Cancer | observational | — | Source → |
| Osimertinib's Effectiveness in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Osimertinib with Chemotherapy Shows Promise in Lung Cancer | Lung Cancer | phase-2 | The objective response rate was 90.9% (95% confidence interval [CI], 84.0-97.8). | Source → |
| Osimertinib Improves Disease-Free Survival in Early-Stage Lung Cancer | Lung Cancer | phase-3 | Osimertinib showed significant and clinically meaningful disease-free survival benefit compared to placebo. | Source → |
| Understanding how cancer drugs selectively target mutated EGFR | Lung Cancer | lab-study | — | Source → |
| Using Computer Models to Improve Cancer Drug Research | Lung Cancer | review | — | Source → |
| Osimertinib Treatment for Lung Cancer: New Insights on PD-L1 Expression | Lung Cancer | observational | The estimated median progression-free survival was 17.1 months. | Source → |
| Combining Osimertinib and Pemetrexed May Help Treat Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Rare Side Effect of Cancer Treatment: Intestinal Haemorrhage and Colitis | Lung Cancer | observational | — | Source → |
| Combining Osimertinib with Pulmonary Rehabilitation Improves Lung Cancer Outcomes | Lung Cancer | observational | Pulmonary function was higher, the incidence of complications was significantly lower, and quality of life scores were markedly higher in patients treated with osimertinib compared to those who received pemetrexed combined with cisplatin. | Source → |
| Rare Lung Cancer Patient Responds to Targeted Therapies | Lung Cancer | observational | Alectinib achieved a nearly complete response for lung and brain lesions. | Source → |
| Cost-effectiveness of osimertinib for lung cancer treatment | Lung Cancer | review | Osimertinib has represented a remarkable increase in progression-free survival (PFS) and a decrease in death and hazard ratios. | Source → |
| Osimertinib Effective for Elderly Lung Cancer Patients | Lung Cancer | observational | The proportion of patients with 1-year progression-free survival was 65.8% (95% confidence interval 57.1-73.5). | Source → |
| Osimertinib May Help Some Lung Cancer Patients Stay Cancer-Free | Lung Cancer | phase-3 | Participants who took osimertinib have stayed cancer-free for longer than those who took the placebo. | Source → |
| Comparing Lung Cancer Treatments: Second- vs Third-Generation EGFR Inhibitors | Lung Cancer | observational | No significant differences in overall survival were observed between the two groups [afatinib vs. osimertinib=36 vs. 33 months (hazard ratio=2.917, 95% confidence interval=0.780-10.905; p=0.112)]. | Source → |
| Blocking a Protein May Help Overcome Lung Cancer Resistance to Osimertinib | Lung Cancer | lab-study | — | Source → |
| Afatinib May Help Some Patients with Lung Cancer Resist Osimertinib | Lung Cancer | observational | — | Source → |
| Combining Osimertinib with Other Treatments May Improve Survival in Lung Cancer Patients | Lung Cancer | observational | Osimertinib-based combination therapy yielded better overall survival (OS) than chemotherapy alone (7.8 months vs. not achieved) | Source → |
| Researchers Target Snail to Overcome Resistance to Osimertinib in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Osimertinib Resistance Linked to Exosome-Derived MicroRNA in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Combining Cancer Drugs Shows Promise in Japanese Patients | Lung Cancer | phase-1 | — | Source → |
| Osimertinib with or without chemotherapy for lung cancer | Lung Cancer | phase-2 | Median PFS was 15.8 months for the osimertinib monotherapy group and 14.6 months for the combination therapy group. | Source → |
| Natural Compound Reverses Resistance to Lung Cancer Treatment | Lung Cancer | lab-study | — | Source → |
| Chemotherapy and targeted therapy may trigger immune response in lung cancer | Lung Cancer | lab-study | — | Source → |
| Osimertinib Effective for Elderly Lung Cancer Patients | Lung Cancer | observational | The overall objective response rate was 60.5%. | Source → |
| Osimertinib Improves Lung Cancer Outcomes for Some Patients | Lung Cancer | review | — | Source → |
| Long-term survival in lung cancer patient with brain metastases | Lung Cancer | observational | — | Source → |
| Cancer Flare Without Visible Signs After Stopping Osimertinib | Lung Cancer | observational | — | Source → |
| Managing Resistance to Lung Cancer Treatment | Lung Cancer | review | — | Source → |
| New Research Advances Treatment for Non-Small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Rare Blood Disorder Linked to Lung Cancer Treatment | Lung Cancer | observational | — | Source → |
| Osimertinib May Be a Viable Second-Line Treatment for Lung Cancer | Lung Cancer | observational | The best tumor response rate was 42.7%, with a median time on treatment of 5.6 months. | Source → |
| Combining Radiation and Osimertinib Treatments for Lung Cancer | Lung Cancer | meta-analysis | Osimertinib and similar third-generation EGFR-TKIs performed better in the brain, helping patients with central nervous system (CNS) responses of 60% to 91%. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.